Legal & General Group
TSBX

Legal & General Group’s Turnstone Biologics TSBX Stock Holding History

Legal & General Group’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-796
Closed -$2.1K – 3507
2024
Q1 		$2.1K Hold
796
– – ﹤0.01% 3347
2023
Q4 		$2.03K Hold
796
– – ﹤0.01% 3367
2023
Q3 		$3.1K Buy
+796
New +$7.09K ﹤0.01% 3388

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Legal & General Group's TSBX Position: Q2 2024 in Review

Legal & General Group sold out of Turnstone Biologics (TSBX) in Q2 2024, closing a stake of 796 shares — an estimated $2.1K sold.

Legal & General Group first reported a position in TSBX in Q3 2023 and held it in 3 quarters. The position peaked at $3.1K in Q3 2023. 47 funds tracked by Wall St. Rank hold TSBX as of Q2 2024.

  • Legal & General Group reported no remaining Turnstone Biologics position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 796 Turnstone Biologics shares in Q2 2024, an estimated $2.1K.
  • Legal & General Group first reported a position in Turnstone Biologics in Q3 2023 and held it in 3 quarters.
  • Legal & General Group's Turnstone Biologics position peaked at $3.1K in Q3 2023.
  • 47 funds tracked by Wall St. Rank held Turnstone Biologics as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.